Top Medical News
Stephen Padilla, an hour ago
The risk of heart failure admission to hospital appears to be lower with canagliflozin in direct comparisons with three different classes of nongliflozin diabetes alternatives including DPP-4 inhibitors (DPP-4i), GLP-1 receptor agonists (GLP-1RA) or sulfonylureas, as used in routine care, a recent study suggests. Moreover, the risk of myocardial infarction or stroke is comparable between canagliflozin and nongliflozin antidiabetic drugs.
3 hours ago
The rates of antibiotic prophylaxis appear to be low among paediatric patients with sickle cell anaemia (SCA), and this is despite national recommendations and established lifesaving benefit of the treatment approach, according to a study.
23 hours ago
Tasmusolin is effective in medical expulsive therapy for distal ureteral stones, showing significantly better expulsion rates for stones >5 mm, a recent study has shown.
2 days ago
Using danazol in addition to thalidomide/prednisone appears to confer benefits for response rates and response duration in patients with primary myelofibrosis (PMF) and anaemia with or without red blood cell (RBC) transfusion dependence, a study has shown.
3 days ago
The use of opioid analgesics among patients with ankylosing spondylitis (AS) appears to be associated with subjective measures (depression, Bath Ankylosing Spondylitis Disease Activity Index [BASDAI], Bath Ankylosing Spondylitis Functional Index [BASFI]) than objective measures (C-reactive protein [CRP], erythrocyte sedimentation rate [ESR]), according to a study.
3 days ago
Use of raloxifene as an augmentation to antipsychotic medication appears to help improve psychotic symptoms in patients with schizophrenia, according to a study.
3 days ago
New drug applications approved by US FDA as of 1 - 15 February 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Special Reports
27 Dec 2017
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
22 Dec 2017
Eczema (atopic dermatitis) is a chronic inflammatory skin disease that can present in many different forms. However, it is principally characterized by dry skin, intense itching, and the presence of inflammatory skin lesions. [J Eur Acad Dermatol Venereol 2016;30:604-618; N Engl J Med 2008;358:1483-1494; Lancet 2016;387:1109-1122]
30 Nov 2017
Fluarex Tetra - Inactivated quadrivalent influenza vaccine (split virion) vaccine (inj) 0.5 mL - GlaxoSmithKline
01 Nov 2017
Since the beginning of the probiotic era in the 20th century, much emphasis has been given on its role in the regulation of gut health. The past decades have seen increasing evidence on the benefits of probiotics beyond just gut health, to even encompass, skin health, memory and brain health, and immunity.
01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute. 
Dr. Yeo Khung Keong, Dr. Wiwun Tungsubutra, Prof. Peter Collins, 31 Aug 2017
Agents such as beta-blockers and calcium antagonists have been the cornerstone of treatment for stable angina for some time. However, new options are emerging for patients who remain inadequately controlled on conventional therapies. At a recent Menarini-sponsored symposium held during the APSC Congress 2017 in Singapore, three experts discussed the current treatment landscape, as well as changing paradigms and new effective options for patients with symptomatic angina.
01 Aug 2017
Complementary medicines are popular among consumers in Malaysia so it is important for pharmacists to be well versed in complementary medicines.
Conference Reports
Pearl Toh, 13 Feb 2018
Combining the anticoagulant rivaroxaban with aspirin reduces the risk of ischaemic stroke by almost half without a significant increase in the risk of intracerebral haemorrhage (ICH) or haemorrhagic transformation compared with aspirin alone in patients with stable coronary artery disease (CAD), according to new data from the COMPASS* study presented at ISC 2018.
Roshini Claire Anthony, 09 Feb 2018

The use of tenecteplase may be a suitable alternative to alteplase prior to endovascular thrombectomy in patients with a large vessel ischaemic stroke, according to results of the EXTEND-IA TNK* study.

Pearl Toh, 09 Feb 2018
Rifaximin, an antibiotic that has been approved for treating IBS-D*, may also benefit patients with Crohn's disease (CD), suggests a study presented at the Crohn's & Colitis Congress (CCC) 2018.
Pearl Toh, 08 Feb 2018
Using the JAK* inhibitor tofacitinib as induction therapy for Crohn’s disease (CD) can promote disease remission in certain patients selected based on baseline endoscopic evidence of inflammation, according to a post hoc analysis presented at the recent Crohn's & Colitis Congress (CCC) 2018, Las Vegas, Nevada, US.
Roshini Claire Anthony, 07 Feb 2018

A combination of the cholesterol-lowering drug rosuvastatin and blood pressure-lowering drugs candesartan and hydrochlorothiazide led to a significant 44 percent reduction in the risk of first strokes among individuals with an intermediate risk of cardiovascular (CV) disease, results from the HOPE-3* study showed.

Roshini Claire Anthony, 06 Feb 2018

The combination of nivolumab and ipilimumab demonstrated strong response, progression-free survival (PFS), and overall survival (OS) rates in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic or recurrent colorectal cancer (CRC), results from the phase II CheckMate-142* trial show.

Roshini Claire Anthony, 30 Jan 2018

The addition of ramucirumab, a fully human IgG1 monoclonal antibody receptor antagonist, to chemotherapy, prolonged progression-free survival (PFS) in individuals with previously untreated metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma, findings from the phase III RAINFALL* trial show. 

CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD